Last Updated: November 13, 2026

EMLA Drug Patent Profile

Which patents cover Emla, and what generic alternatives are available?

Emla is a drug marketed by Teva Branded Pharm and Astrazeneca and is included in two NDAs.

The generic ingredient in EMLA is lidocaine; prilocaine. Thirteen suppliers are listed for this compound. Additional details are available on the lidocaine; prilocaine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Emla

A generic version of EMLA was approved as lidocaine; prilocaine by FOUGERA PHARMS on August 18^th, 2003.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for EMLA?
What are the global sales for EMLA?
What is Average Wholesale Price for EMLA?

Summary for EMLA

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for EMLA

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	EMLA	lidocaine; prilocaine	CREAM;TOPICAL	019941-001	Dec 30, 1992		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Astrazeneca	EMLA	lidocaine; prilocaine	DISC;TOPICAL	020962-001	Feb 4, 1998		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for EMLA

See the table below for patents covering EMLA around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Argentina	218948	PROCEDIMIENTO PARA LA OBTENCION DE PREPARACIONES ACTIVAS DE ENESTESIA LOCAL	⤷ Start Trial
Austria	364451		⤷ Start Trial
Austria	A859578		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.